Form 4: Director Leslie Norwalk Receives NBIX Equity Grant
Statement of Changes in Beneficial Ownership
Neurocrine Biosciences director Leslie V. Norwalk was granted restricted stock units and stock options as part of annual compensation.
Summary
- Director Leslie V. Norwalk received an equity grant on May 27, 2026.
- The grant includes 1,284 Restricted Stock Units (RSUs) which vest in full on May 27, 2027.
- The grant includes 2,624 Non-Qualified Stock Options with an exercise price of $155.83.
- The stock options vest in 12 monthly installments beginning June 27, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard corporate governance and compensation practices.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Minor dilution of existing shareholders upon the eventual exercise and vesting of these equity instruments.
Risks
- Market volatility affecting the value of the granted equity instruments.
- Potential for future share price fluctuations impacting the exercise value of the options.
Future Outlook
The filing does not provide forward-looking business guidance, as it is a standard disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure director retention and alignment with long-term corporate performance goals.
Comparison to Industry Standards
- The grant structure of combining RSUs and options is consistent with standard executive and director compensation packages in the mid-to-large cap biotech industry.
- Vesting schedules are typical for industry-standard director compensation plans.
Stakeholder Impact
- Minimal impact on shareholders due to the relatively small size of the equity grant.
Next Steps
- Vesting of stock options beginning June 27, 2026.
- Vesting of RSUs on May 27, 2027.
Key Dates
| Date | Description |
|---|---|
| 2026-05-27 | Date of grant for RSUs and stock options. |
| 2026-06-27 | Commencement of monthly vesting for stock options. |
| 2027-05-27 | Full vesting date for Restricted Stock Units. |
| 2036-05-27 | Expiration date for the granted stock options. |
Keywords
Neurocrine Biosciences, NBIX, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.